This is well illustrated in one of the earliest clinical trials determining urine and plasma NGAL, where a very early rise in renal and plasma NGAL predicted evolving CAN in children with congenital heart disease undergoing cardiac imaging with contrast media [39]. Here, LCN2 is linked to congenital heart disease.